For injectable medications, bioavailability is generally high (close to 100% for subcutaneous injections) because the drug is delivered directly into tissue without needing to pass through the gastrointestinal tract or first-pass metabolism
The Alzheimers question, still unsettled The brain volume story does not yet extend cleanly to Alzheimers disease
Although advancements have been made in targeting DNA repair mechanisms to treat GBM through chemotherapy, such conventional treatments also involving surgical interventions and radiotherapy have yet to yield consistently satisfactory outcomes [166]
Reports related to PD-1 inhibitorsnivolumab, pembrolizumab, cemiplimab, toripalimab, and tislelizumabwere more frequent than those involving PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab), accounting for approximately 76.5% and 23.5% of cases, respectively
In MS research, tolerogenic peptide approaches targeting myelin basic protein have shown early promise